Abstract: Provided are methods for treating or preventing vasculopathy comprising administering to a subject in need thereof, ac composition comprising a mesenchymal stem cell (MSC), or a part of a culture medium that has been in contact with the MSC and comprises one or more components of the MSC, or an exosome derived from the MSC. Pharmaceutical compositions suitable for such treatment is also provided.

Abstract: Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.

Abstract: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.

Abstract: A method is disclosed for separating cells from a lung. Mechanical pressure can be used in one stage of the process to increase the yield of separated cells, including alveolar type II cells.

Abstract: Systems and methods are provided for evaluating a tissue that utilize a resistance to represent pressure of a fluid or gas passing through the tissue and a capacitance to represent compliance of the tissue.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: A system comprises a fluid supply, a pressure regulator, a pressure valve, and a vent assembly. The fluid supply stores a volume of a fluid and is fluidly coupled to an outlet tube. The outlet tube is configured to be fluidly coupled to at least a portion of an organ environment. The organ environment configured to hold an organ. The pressure regulator is fluidly coupled to the outlet tube and is configured to maintain a fluid pressure of the fluid being supplied to the organ environment from the outlet tube. The fluid being supplied is at a pressure range above ambient to maintain the organ in an inflated position. The pressure valve is fluidly coupled to the outlet tube and inhibits increase of the fluid pressure above a threshold. The vent assembly removes excess fluid from the organ environment and includes a vent tube disposed within the organ environment and a vent valve disposed outside of the organ environment.

Abstract: A drug-delivery device comprising a drug-reservoir assembly, displacement-generating actuator, and drug administration unit is described, wherein the drug-reservoir assembly comprises at least one flexible wall and a constraining ring, such that the displacement generated by the actuator collapses a flexible wall of the assembly expelling the drug contents of the drug-reservoir towards said drug administration means.

Abstract: Provided are methods for treating or preventing vasculopathy comprising administering to a subject in need thereof , ac composition comprising a mesenchymal stem cell (MSC), or a part of a culture medium that has been in contact with the MSC and comprises one or more components of the MSC, or an exosome derived from the MSC. Pharmaceutical compositions suitable for such treatment is also provided.

Abstract: Provided are novel prodrugs of esuberaprost and pharmaceutical compositions thereof, as well as methods of making and methods of using these prodrugs.

Abstract: The present application provides a self-powered drug-delivery device. The device includes a chamber having a wall. The chamber contains a fluid and is in connection with an administration means. The device also includes a displacement-generating battery cell. The device further includes an electrically-controlled battery unit, which includes the displacement-generating battery cell coupled to the chamber by a coupling means. The displacement-generating battery cell includes an element that changes shape as a result of charge or discharge of the battery cell so as to cause a displacement within the battery unit. The arrangement of the battery unit, the coupling means, the wall, the chamber, and the administration means is such that the displacement derived from the battery unit is conveyed by the coupling means to cause displacement of the wall of the chamber such that the fluid is expelled from the chamber to force a drug towards the administration means.

Abstract: Described herein are noninvasive electrical stimulation devices, systems and methods for stimulation of the Vagus nerve through its auricular branch to provide beneficial physiological responses in subjects, including alleviation, mitigation or elimination of symptoms of various disorders, including metabolic and inflammatory disorders.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.

Abstract: This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing

Abstract: Provided are treprostinil derivatives with a reduced ability to form undesired impurities in a pharmaceutical formulation, such as a dry powder formulation, further containing a carboxyl group containing inactive ingredient, such as fumaryl diketopiperazine.

Abstract: Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Abstract: Provided are methods for treating or preventing myocarditis by administering extracellular vesicles, including exosomes. In some embodiments, the EVs are from bone marrow-derived mesenchymal stem (or stromal) cells. The myocarditis can be the result of viral infections such as Coxsackievirus B virus, SARS-CoV-2, or other viruses.

Abstract: The present disclosure provides regioselective methods for synthesizing intermediates useful in making prostacyclin derivatives, such as treprostinil.

Abstract: An adjustable aerosol delivery device includes an active liquid container, a carrier liquid container, a piezo disc mounted with a flexible gasket relative to the carrier liquid container, an oscillator configured to generate an ultrasonic wave that causes the piezo disc to oscillate and transmit the oscillations through the carrier liquid to the active liquid to cause at least a portion of the active liquid to become an aerosol, a bushing fixed relative to the carrier liquid container via a fixing portion that conforms to and mates with an entire perimeter of a fixing section of the bushing, and a fastener extending through the piezo disc housing and into the bushing. The fastener is configured to be loosened or tightened to manipulate a compression of the gasket to adjust a particle size of the aerosol. A pull force of the bushing is greater than a counter force of the gasket.